All In Biotech

Drug Trial Radar · NCT07555938

Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma

A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Patients With Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 380 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

380

Planned (sponsor's estimate)

Start

Jun 23, 2026

Primary completion

Nov 30, 2028

Study completion Jan 31, 2033

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Apr 29, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the efficacy and safety of cevostamab in combination with pomalidomide and dexamethasone (CevosPd) versus standard of care (SOC) in participants with multiple myeloma (MM) who have received one to three prior lines of therapy and have been exposed to an anti-CD38 monoclonal antibody (mAb) and lenalidomide.

Conditions

  • Multiple Myeloma

Interventions

  • CevostamabDrug

    Participants will receive cevostamab IV as per the schedule given in the protocol.

  • PomalidomideDrug

    Participants will receive pomalidomide tablet orally PO as per the schedule given in the protocol.

  • DexamethasoneDrug

    Participants will receive dexamethasone tablet orally PO or IV as per the schedule given in the protocol.

  • DaratumumabDrug

    Participants will receive daratumumab SC as per the schedule given in the protocol.

  • ElotuzumabDrug

    Participants will receive elotuzumab IV as per the schedule given in the protocol.

  • CarfilzomibDrug

    Participants will receive carfilzomib IV as per the schedule given in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Minimal Residual Disease (MRD)-Negative Complete Response (CR) RateTime frame: Up to 1 year after the last participant is randomized
  2. Progression-Free Survival (PFS)Time frame: Up to 5 years after the last participant is randomized

Locations

105 sites in 18 countries. Site status is shown where the registry gives one.

  • City of Hope National Medical Center

    Duarte, California · Recruiting

  • City of Hope - Lennar Foundation Cancer Center

    Irvine, California · Recruiting

  • Yale University

    New Haven, Connecticut · Recruiting

  • MedStar Washington Hospital Center MedStar Georgetown Cancer Institute

    Washington D.C., District of Columbia · Recruiting

  • Emory University Hospital Midtown

    Atlanta, Georgia · Recruiting

  • University of Illinois

    Chicago, Illinois · Recruiting

  • Novant Health Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Forsythe Memorial Hospital Inc., dba Novant Health Oncology Specialists

    Winston-Salem, North Carolina · Recruiting

  • TriHealth Cancer and Blood Institute

    Cincinnati, Ohio · Recruiting

  • Perelman Center for Advanced Medicine

    Philadelphia, Pennsylvania · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Texas Tech University Health Sciences Center

    Lubbock, Texas · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

  • Medical College of Wisconsin

    Milwaukee, Wisconsin · Recruiting

  • St Vincent's Hospital Melbourne

    Fitzroy, Victoria, Australia · Recruiting

  • The Alfred Hospital

    Melbourne, Victoria, Australia · Recruiting

  • Americas Centro de Oncologia Integrado

    Rio de Janeiro, Brazil · Recruiting

  • Hospital Israelita Albert Einstein

    São Paulo, São Paulo, Brazil · Recruiting

  • Hamilton Health Sciences - Juravinski Cancer Centre

    Hamilton, Ontario, Canada · Recruiting

  • Nanfang Hospital, Southern Medical University

    Guangzhou, China · Recruiting

  • Qilu Hospital of Shandong University

    Jinan, China · Recruiting

  • The First Affiliate Hospital of Guangxi Medical University

    Nanning, China · Recruiting

  • Zhongshan Hospital Fudan University

    Shanghai, China · Recruiting

  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

  • The First Affiliated Hospital of Soochow University

    Suzhou, China · Recruiting

  • The First Affiliated Hospital of Wenzhou Medical University

    Wenzhou, China · Recruiting

  • Tongji Hospital Tongji Medical College Huazhong University of Science and Technology

    Wuhan, China · Recruiting

  • Sun yat-sen University Cancer Center

    Guangzhou, Guangdong, China · Recruiting

  • Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School

    Nanjing, Jiangsu, China · Recruiting

  • The Affiliated Hospital Of Qingdao University

    Qingdao, Shandong, China · Recruiting

  • Tianjin Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • The First Affilliated Hospital of Kunming Medical University

    Kunming, Yunnan, China · Recruiting

  • The First Affiliated Hospital, Zhejiang University School of Medicine - Qingchun Campus - PPDS

    Hangzhou, Zhejiang, China · Recruiting

  • Fakultni nemocnice Brno

    Brno, Czechia · Recruiting

  • Fakultni nemocnice Hradec Kralove

    Hradec Králové, Czechia · Recruiting

  • Fakultni nemocnice Ostrava

    Ostrava, Czechia · Recruiting

  • Aarhus Universitetshospital

    Aarhus, Denmark · Recruiting

  • Rigshospitalet

    København Ø, Denmark · Recruiting

  • Sjællands Universitetshospital, Køge;Hæmatologisk afdeling

    Køge, Denmark · Recruiting

  • Sygehus Lillebælt, Vejle;Hæmatologisk Forskningsenhed, HKFE

    Vejle, Denmark · Recruiting

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.